New research estimates the enormous financial and human burden associated with opioid prescribing in Britain. Now, healthcare researchers are questioning whether patients experiencing everyday pain could benefit from a different approach before stronger medicines enter the picture.
Pain has a rather unpleasant talent for taking over ordinary life. It interrupts sleep, makes work harder and can turn a perfectly routine movement into something that requires considerable thought.
For millions of people across Britain, that is familiar territory. Finding effective relief matters enormously. But so does understanding the consequences of the medicines used to provide it.
New economic modelling from York Health Economics Consortium (YHEC), based at the University of York, estimates that the annual burden associated with opioid prescribing in the UK has reached approximately £1.17 billion.
Meanwhile, a research paper published on 8 October 2026 in the Journal of Community Medicine & Public Health is questioning whether existing approaches to pain management could be improved by introducing non-opioid combination treatments earlier.
The question is straightforward enough: could more patients find adequate pain relief without progressing unnecessarily to opioid medication?
The answer deserves considerably more attention than another alarming headline.
The £1.17bn Cost Behind UK Opioid Prescribing
More than 5.3 million people are prescribed opioids in the UK each year, according to the YHEC analysis.
These medicines have an established place in treating certain types of pain. However, they also carry risks, particularly when treatment continues for extended periods.
The latest economic assessment attempts to quantify the wider consequences.
Of the estimated £1.17 billion annual burden, approximately £447 million relates directly to opioid prescriptions, making medication costs the largest individual component.
Another £343 million is attributed to counselling associated with drug misuse, while the model also considers hospital admissions, GP appointments, work absence and other consequences.
The distinction matters. The £1.17 billion figure is a modelled estimate of healthcare and societal costs, not a calculation of how much the NHS spends unnecessarily on opioids. It includes costs associated with appropriate prescribing as well as misuse.
YHEC separately estimates that unnecessary opioid prescribing costs the NHS approximately £240 million annually.
There is also a potentially significant opportunity for savings. The researchers modelled a scenario in which opioid prescribing was delayed or reduced by two weeks, calculating an estimated annual saving of £24 million.
That is a projection rather than a saving already achieved, and it does not establish that a particular alternative treatment would deliver the same financial result.
Nevertheless, the figures provide a substantial reason to examine how pain relief is prescribed.
Why Does Opioid Prescribing Vary So Much Across Britain?
The geographical differences uncovered by the research are particularly striking.
Among patients registered with the Norfolk and Suffolk Integrated Care Board, the analysis identified an opioid prescribing prevalence of 12.7%.
In West and North London, the equivalent figure was 5.39%.
That is a considerable difference between two areas operating within the same national healthcare system.
The research also identified a substantial relationship between deprivation and prescribing costs. The most deprived fifth of the population accounted for approximately 33% of the total estimated economic burden, equivalent to £388 million.
These findings raise legitimate questions about access, prescribing practices and variations in clinical decision-making. They do not, however, establish that individual prescriptions are inappropriate or that geography alone explains the difference. Patients’ clinical needs and population characteristics also require consideration.
Dr Nisa Aslam, a GP and co-author of the new research paper, believes the variation warrants closer examination.
“These wide variations suggest that a patient’s postcode, rather than the severity of their pain or their clinical need, may determine whether they are offered an opioid for mild-to-moderate and chronic non-cancer pain. Decisions like this should be based on evidence, not geography.”
For patients, consistency matters. Someone seeking relief from persistent pain should be able to expect decisions grounded in their clinical circumstances rather than unexplained variations between regions.
Could the NHS Pain Management Pathway Be Reconsidered?
The newly published paper, Next-Generation Mild-to-Moderate Pain Management Pathway: A Strategy for Reversing the Opioid Crisis, proposes a different approach to treating mild-to-moderate pain.
Written by pharmacy researcher Dr Pamela Mason, Dr Nisa Aslam, GP Dr Janine David and pharmacist Mark Burdon, it examines how prescribing guidance might reduce unnecessary exposure to opioids.
The authors argue that some approaches to pain management still resemble the World Health Organization’s traditional analgesic ladder, originally developed primarily for cancer pain.
In certain treatment pathways, patients whose symptoms are not adequately controlled by paracetamol or an anti-inflammatory medicine such as ibuprofen may progress to an opioid, including codeine.
The researchers propose introducing another option before that escalation.
Their suggested pathway would make greater use of a fixed-dose combination of paracetamol and ibuprofen after initial treatment with individual non-opioid medicines has proved insufficient, where clinically appropriate.
One product discussed is Combogesic, an over-the-counter medicine containing 500mg of paracetamol and 150mg of ibuprofen per tablet.
The two ingredients act through different mechanisms. Combining them may provide more effective relief than either ingredient alone for certain types of pain.
Importantly, this remains a proposal from the paper’s authors, rather than an announced change to NHS prescribing guidance.
What Does the Evidence Actually Show?
There is clinical research supporting the effectiveness of fixed-dose paracetamol and ibuprofen combinations, particularly for acute pain.
One randomised trial involving 408 adults experiencing pain following wisdom tooth removal found that the combination provided better pain control than paracetamol or ibuprofen alone.
A pooled analysis of four studies involving 922 patients also examined the need for additional opioid pain relief. At least one dose of rescue oxycodone was required by 34% of patients receiving the combination, compared with 50% receiving paracetamol alone and 39% receiving ibuprofen alone.
That suggests a potentially useful role in reducing opioid requirements in the circumstances studied.
But there is an important distinction between demonstrating improved pain relief after dental surgery and proving that the same treatment strategy will reduce long-term opioid dependence across the NHS.
The available evidence should not be stretched beyond the conditions in which it was collected.
There are safety considerations, too. Ibuprofen is associated with gastrointestinal risks, particularly at higher doses, and combining established painkillers does not automatically make treatment appropriate for everybody.
Any revised pathway would still need to account for contraindications, other medical conditions, existing medication and individual patient needs.
Commercial involvement also deserves transparency. The economic research was commissioned in connection with Combogesic, while the journal authors acknowledge receiving an educational grant from AFT Pharmaceuticals, which markets the medicine. The paper states that AFT Pharmaceuticals played no role in producing the publication.
That relationship does not invalidate the clinical research. It does make independent scrutiny and real-world evidence particularly important before broader changes are recommended.
Better Pain Relief Should Be the Starting Point
Behind the spending estimates sits a more immediate problem: pain affects people’s ability to sleep, work, move comfortably and enjoy everyday life.
Reducing inappropriate opioid prescribing is an important objective, but it cannot come at the expense of leaving patients without effective treatment.
Nor should people currently taking prescribed opioids interpret the research as a reason to stop their medication independently. Changes to ongoing treatment, particularly where dependence or withdrawal may be a concern, require appropriate clinical supervision.
The proposed pathway is an invitation to examine how treatment decisions are made, not a universal replacement for opioid medicines.
Further evidence would be needed to establish whether introducing non-opioid combinations earlier improves outcomes across different pain conditions, reduces long-term prescribing and delivers the projected savings in routine NHS care.
The YHEC figures have given the debate financial weight. The more important test is whether a revised approach can provide appropriate relief for patients while reducing avoidable harm.
Ultimately, the purpose of pain management is not simply to prescribe fewer medicines. It is to help people live better with less pain.
